IL2 and cancer: Distinct patterns of immune activation and regulation are evident between cancer types, with melanoma patients generally exhibiting stronger pro-inflammatory responses (e.g., IL-2 and TNF-α elevations), while IL-10 dynamics suggest differential regulatory feedback.